Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus.

Bibliographic Details
Title: Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus.
Authors: Mukhopadhyay, Shreya, Manolaridis, Ioannis, Warren, Christopher, Tang, Aimin, O'Donnell, Gregory, Luo, Bin, Staupe, Ryan P., Vora, Kalpit A., Chen, Zhifeng
Source: Vaccines; Jan2025, Vol. 13 Issue 1, p35, 18p
Subject Terms: CLINICAL trials, RESPIRATORY infections in children, RESPIRATORY syncytial virus, BOOSTER vaccines, RESPIRATORY infections
Abstract: Background/Objectives: The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children and adults. With nearly everyone infected by the age of five, there is an opportunity to develop booster vaccines that enhance B-cell immunity, promoting potent and broadly neutralizing antibodies. One potential approach involves using anti-idiotypic antibodies (anti-IDs) to mimic specific antigenic sites and enhance preexisting immunity in an epitope-specific manner. RB1, a monoclonal antibody (mAb) that binds to site IV of the RSV fusion (RSV F) protein, is a potent and broadly neutralizing against RSV A and B viruses. It is the precursor for MK1654 (clesrovimab), which successfully completed a Phase III clinical trial. Methods: In this study, we isolated two anti-IDs, 1A6 and 1D4, targeting RB1 CDR regions, demonstrating that 1A6 competes fully with RSV F in binding to RB1. Results: We resolved the RB1-1A6 and RB1-1D4 Fab-Fab complex structures and proved that 1A6 mimics the RSV F site IV better than 1D4. In an immunogenicity study, mice primed with RSV F and boosted with 1A6 Fab showed a site IV-specific antibody response with a concurrent increase in RSV virus neutralization. Conclusions: These results suggest that anti-IDs could be potentially used as booster vaccines for specific epitopes. [ABSTRACT FROM AUTHOR]
Copyright of Vaccines is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:2076393X
DOI:10.3390/vaccines13010035
Published in:Vaccines
Language:English